1,416 results match your criteria Imaging in Oligodendroglioma

Deuterium metabolic imaging reports on TERT expression and early response to therapy in cancer.

Clin Cancer Res 2022 Jun 9. Epub 2022 Jun 9.

University of California, San Francisco, San Francisco, United States.

Purpose: Telomere maintenance is a hallmark of cancer. Most tumors maintain telomere length via reactivation of telomerase reverse transcriptase (TERT) expression. Identifying clinically translatable imaging biomarkers of TERT can enable non-invasive assessment of tumor proliferation and response to therapy. Read More

View Article and Full-Text PDF

Bilateral oligodendroglial hamartomas: A rare cause of drug-resistant epilepsy in a pediatric patient.

J Clin Imaging Sci 2022 5;12:24. Epub 2022 May 5.

Department of Imaging Sciences, University of Rochester Medical Center, Rochester, New York, United States.

Intractable or drug-resistant seizures in pediatric patients are often secondary to cortical malformations, hamartomas, or mass lesions. Various subtypes of intracerebral hamartomas, associated with seizure disorders, have been described. In this report, we describe a subtype of intracerebral hamartoma associated with intractable epilepsy in a 10-year-old patient. Read More

View Article and Full-Text PDF

Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.

Sci Rep 2022 Jun 2;12(1):9197. Epub 2022 Jun 2.

Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

This study aimed to determine whether quantitative relaxometry using synthetic magnetic resonance imaging (SyMRI) could differentiate between two diffuse glioma groups with isocitrate dehydrogenase (IDH)-mutant tumors, achieving an increased sensitivity compared to the qualitative T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign. Between May 2019 and May 2020, thirteen patients with IDH-mutant diffuse gliomas, including seven with astrocytomas and six with oligodendrogliomas, were evaluated. Five neuroradiologists independently evaluated the presence of the qualitative T2-FLAIR mismatch sign. Read More

View Article and Full-Text PDF

Reproducibility of 3 T APT-CEST in Healthy Volunteers and Patients With Brain Glioma.

J Magn Reson Imaging 2022 May 28. Epub 2022 May 28.

Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Background: Amide proton transfer (APT) imaging is a chemical exchange saturation transfer (CEST) technique offering potential clinical applications such as diagnosis, characterization, and treatment planning and monitoring in glioma patients. While APT-CEST has demonstrated high potential, reproducibility remains underexplored.

Purpose: To investigate whether cerebral APT-CEST with clinically feasible scan time is reproducible in healthy tissue and glioma for clinical use at 3 T. Read More

View Article and Full-Text PDF

A Novel Method Based on GAN Using a Segmentation Module for Oligodendroglioma Pathological Image Generation.

Sensors (Basel) 2022 May 23;22(10). Epub 2022 May 23.

Graduate School of Smart Convergence, Kwangwoon University, Seoul 01897, Korea.

Digital pathology analysis using deep learning has been the subject of several studies. As with other medical data, pathological data are not easily obtained. Because deep learning-based image analysis requires large amounts of data, augmentation techniques are used to increase the size of pathological datasets. Read More

View Article and Full-Text PDF

Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.

Turk Neurosurg 2022 ;32(3):500-507

Istanbul University, Istanbul Faculty of Medicine, Department of Neurosurgery, Istanbul, Turkey.

Aim: To evaluate isocitrate dehydrogenase (IDH) mutation status and Ki67 percentages of tumors that were treated in our institution to determine whether these markers affected the initial diagnosis and survival rates.

Material And Methods: High-grade glioma patients, who were operated in our department between 2013 and 2018, were enrolled in the study and retrospectively reviewed. New immunohistochemistry staining studies were conducted and survival analyses were performed. Read More

View Article and Full-Text PDF

Diffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication.

Eur Radiol 2022 May 19. Epub 2022 May 19.

Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Objectives: To determine whether imaging-based risk stratification enables prognostication in diffuse glioma, NOS (not otherwise specified).

Methods: Data from 220 patients classified as diffuse glioma, NOS, between January 2011 and December 2020 were retrospectively included. Two neuroradiologists analyzed pre-surgical CT and MRI to assign gliomas to the three imaging-based risk types considering well-known imaging phenotypes (e. Read More

View Article and Full-Text PDF

Towards real-time intraoperative tissue interrogation for REIMS-guided glioma surgery.

J Mass Spectrom Adv Clin Lab 2022 Apr 29;24:80-89. Epub 2022 Apr 29.

Maastricht MultiModal Molecular Imaging (M4I) Institute, Division of Imaging Mass Spectrometry, Maastricht University, 6229 ER Maastricht, The Netherlands.

Introduction: The main goal of brain tumour surgery is to maximize tumour resection while avoiding neurological deficits. Accurate characterization of tissue and delineation of resection margins are, therefore, essential to achieve optimal surgical results.

Objectives: The primary objective of this study was to develop and validate a mass spectrometry- based technique for the molecular characterization of high- and low-grade glioma tissue during surgery. Read More

View Article and Full-Text PDF

Relationship between histological tumor margins and magnetic resonance imaging signal intensities in brain neoplasia of dogs.

J Vet Intern Med 2022 May 30;36(3):1039-1048. Epub 2022 Apr 30.

Department of Biomedical Sciences, Section of Anatomic Pathology, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.

Background: Intracranial neoplasia is relatively common in dogs and stereotactic radiotherapy, surgical debulking, or both, are the most successful treatment approaches. A key component of treatment planning involves delineating tumor margin on magnetic resonance imaging (MRI) examinations. How MRI signal intensity alterations relate to histological tumor margins is unknown. Read More

View Article and Full-Text PDF

Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas.

Front Neurol 2022 30;13:822362. Epub 2022 Mar 30.

Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Background: An integrated diagnosis consisting of histology and molecular markers is the basis of the current WHO classification system of gliomas. In patients with suspected newly diagnosed or recurrent glioma, stereotactic biopsy is an alternative in cases in which microsurgical resection is deemed to not be safely feasible or indicated. In this retrospective study, we aimed to analyze both the diagnostic yield and the safety of a standardized biopsy technique. Read More

View Article and Full-Text PDF

Gyriform infiltration as imaging biomarker for molecular glioblastomas.

J Neurooncol 2022 May 1;157(3):511-521. Epub 2022 Apr 1.

Department of Neuro-Oncology, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France.

Background: Molecular glioblastomas (i.e. without the histological but with the molecular characteristics of IDH-wild-type glioblastoma) frequently lack contrast enhancement, which can wrongly lead to suspect a lower-grade glioma. Read More

View Article and Full-Text PDF

Extraventricular neurocytoma at the sellar region: Report of 8 cases and literature review.

J Clin Neurosci 2022 May 30;99:379-386. Epub 2022 Mar 30.

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brain Tumor, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Electronic address:

Background: Extraventricular neurocytoma at the sellar region (EVNSR) is an exceedingly rare tumor. Given the paucity of specificity and its peculiar nature, our study aimed to characterize the clinical, imaging, and pathological features, including treatment and clinical outcomes of this tumor.

Method: Eight patients with pathologically confirmed EVNSR at Beijing Tiantan Hospital from 2012 to 2020 were retrospectively analyzed. Read More

View Article and Full-Text PDF

Detection of Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances.

Biomedicines 2022 Mar 21;10(3). Epub 2022 Mar 21.

Chair of Chemistry of Natural Compounds, Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.

This article reviews the existing approaches to determining the promoter mutational status in patients with various tumoral diseases of the central nervous system. The operational characteristics of the most common methods and their transferability in medical practice for the selection or monitoring of personalized treatments based on the status and other related molecular biomarkers in patients with the most common tumors, such as glioblastoma, oligodendroglioma, and astrocytoma, are compared. The inclusion of new molecular markers in the course of CNS clinical management requires their rapid and reliable assessment. Read More

View Article and Full-Text PDF

Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.

Neurol Med Chir (Tokyo) 2022 Apr 22;62(4):177-185. Epub 2022 Feb 22.

Department of Neurosurgery, Shiga University of Medical Science.

Malignant progression of diffuse low-grade glioma (LGG) is a critical event affecting patient survival; however, the incidence and related factors have been inconsistent in literature. According to the PRISMA guidelines, we systematically reviewed articles from 2009, meta-analyzed the incidence of malignant progression, and clarified factors related to the transformation. Forty-one articles were included in this study (n = 7,122; n, number of patients). Read More

View Article and Full-Text PDF

T2 FLAIR Hyperintensity Volume Is Associated With Cognitive Function and Quality of Life in Clinically Stable Patients With Lower Grade Gliomas.

Front Neurol 2021 28;12:769345. Epub 2022 Jan 28.

Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States.

Survival outcomes for patients with lower grade gliomas (LrGG) continue to improve. However, damage caused both by tumor growth and by the consequences of treatment often leads to significantly impaired cognitive function and quality of life (QoL). While neuropsychological testing is not routine, serial clinical MRIs are standard of care for patients with LrGG. Read More

View Article and Full-Text PDF
January 2022

Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.

CNS Oncol 2022 03 10;11(1):CNS83. Epub 2022 Feb 10.

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

To illustrate challenges of imaging interpretation in patients with oligodendroglioma seen at a referral center and evaluate interrater reliability. Two neuro-oncologists reviewed diagnostic preradiation MRIs of oligodendroglioma patients; interrater reliability was calculated with the kappa coefficient (k). A neuroradiologist measured presurgical apparent diffusion coefficient (ADC), if available. Read More

View Article and Full-Text PDF

Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.

Neuro Oncol 2022 Jul;24(7):1035-1047

Department of Neurology, Division of Neuro-Oncology, University of Virginia, Charlottesville, Virginia, USA.

With improved outcome following aggressive treatment in patients with grade 2 and 3 IDH-mutant (IDHmt), 1p/19q codeleted oligodendroglioma and IDHmt, non-codeleted astrocytoma, prolonged surveillance is desirable for early detection of tumor growth and malignant transformation. Current National Comprehensive Cancer Network (NCCN) guidelines provide imaging follow-up recommendations based on molecular classification of lower-grade gliomas, although individualized imaging guidelines based on treatments received and after tumor recurrence are not clearly specified. Other available guidelines have yet to incorporate the molecular biomarkers that inform the WHO classification of gliomas, and in some cases do not adequately consider current knowledge on IDHmt glioma growth rate and recurrence patterns. Read More

View Article and Full-Text PDF

Radiomics and Qualitative Features From Multiparametric MRI Predict Molecular Subtypes in Patients With Lower-Grade Glioma.

Front Oncol 2021 21;11:756828. Epub 2022 Jan 21.

Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Background: Isocitrate dehydrogenase (IDH) mutation and 1p19q codeletion status have been identified as significant markers for therapy and prognosis in lower-grade glioma (LGG). The current study aimed to construct a combined machine learning-based model for predicting the molecular subtypes of LGG, including (1) IDH wild-type astrocytoma (IDHwt), (2) IDH mutant and 1p19q non-codeleted astrocytoma (IDHmut-noncodel), and (3) IDH-mutant and 1p19q codeleted oligodendroglioma (IDHmut-codel), based on multiparametric magnetic resonance imaging (MRI) radiomics, qualitative features, and clinical factors.

Methods: A total of 335 patients with LGG (WHO grade II/III) were retrospectively enrolled. Read More

View Article and Full-Text PDF
January 2022

Cranial sonolucent prosthesis: a window of opportunity for neuro-oncology (and neuro-surgery).

J Neurooncol 2022 Feb 26;156(3):529-540. Epub 2022 Jan 26.

Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.

Introduction: Ultrasound (US) is a versatile technology, able to provide a real-time and multiparametric intraoperative imaging, and a promising way to treat neuro-oncological patients outside the operating room. Anyhow, its potential is limited both in imaging and therapeutic purposes by the existence of the bone shielding. To enhance the spectrum of uses, our group has designed a dedicated US-translucent cranial prosthesis. Read More

View Article and Full-Text PDF
February 2022

Can Apparent Diffusion Coefficient Predict the Grade, Genotype, or Proliferation Index of Oligodendrogliomas.

Asian J Neurosurg 2021 Oct-Dec;16(4):752-758. Epub 2021 Dec 18.

Department of Surgery, Aga Khan University Hospital, Stadium Road, Karachi, Pakistan.

Background: Genetic subsets of oligodendrogliomas (OD) have distinct chromosomal and biophysical profiles. Pretherapeutic tumor grade and genotype analysis is a challenging aspect of management, with 1p/19q codeletion status and grade of oligodendroglioma among the most important considerations for clinical decision making.

Methodology: Seventy-three patients with histopathological diagnosis of oligodendroglioma were selected, and their preoperative 1. Read More

View Article and Full-Text PDF
December 2021

CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.

Eur J Nucl Med Mol Imaging 2022 Jun 14;49(7):2377-2391. Epub 2022 Jan 14.

Box65, Lysholm Department of Neuroradiology, The National Hospital for Neurology & Neurosurgery, University College London Hospitals NHS Foundation Trust, 8-11 Queen Square, London, WC1N 3BG, UK.

Purpose: Accurate glioma classification affects patient management and is challenging on non- or low-enhancing gliomas. This study investigated the clinical value of different chemical exchange saturation transfer (CEST) metrics for glioma classification and assessed the diagnostic effect of the presence of abundant fluid in glioma subpopulations.

Methods: Forty-five treatment-naïve glioma patients with known isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status received CEST MRI (B = 2μT, T = 3. Read More

View Article and Full-Text PDF

Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.

BMC Neurol 2022 Jan 13;22(1):24. Epub 2022 Jan 13.

Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, NSW, 2065, Australia.

Background: The impact of near-total resection of IDH-mutated anaplastic glioma (IDHmutAG) is well-established but there remains uncertainty of benefit in tumours of the insular cortex where the extent of safe resection may be limited. This study aimed to assess tumour volume reduction in patients following IMRT and impact of residual post-surgical volume.

Methods And Materials: Patients with IDHmutAG involving insular cortex managed with IMRT from 2008 to 2019 had baseline patient, tumour and treatment factors recorded. Read More

View Article and Full-Text PDF
January 2022

A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature.

Brain Tumor Pathol 2022 Apr 11;39(2):111-119. Epub 2022 Jan 11.

Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020, Salzburg, Austria.

Here, we report on a patient presenting with two histopathologically distinct gliomas. At the age of 42, the patient underwent initial resection of a right temporal oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade II followed by adjuvant radiochemotherapy with temozolomide. 15 months after initial diagnosis, the patient showed right hemispheric tumor progression and an additional new left frontal contrast enhancement in the subsequent imaging. Read More

View Article and Full-Text PDF

De novo aphasic status epilepticus: Finally making the diagnosis by long-term EEG.

Epilepsy Behav Rep 2022 8;17:100513. Epub 2021 Dec 8.

Department of Epileptology (Krankenhaus Mara), Bielefeld University, Medical School, Campus Bielefeld-Bethel, Maraweg 21, 33617 Bielefeld, Germany.

Aphasic status epilepticus (SE) is a rare manifestation of non-convulsive SE (NCSE) and may occasionally be under-recognized. We report a 69-year-old male patient with a pre-existing left parietal oligodendroglioma WHO III after two resections and radio-chemotherapy. The patient was left with some word finding difficulties but had no history of overt seizures. Read More

View Article and Full-Text PDF
December 2021

Diffuse leptomeningeal glioneuronal tumor without KIAA1549-BRAF fusion and 1p detection: a case report and review of literature.

Childs Nerv Syst 2022 02 3;38(2):279-285. Epub 2022 Jan 3.

Department of Radiology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, China International Science and Technology Cooperation Base of Child development and Critical Disorders, Chongqing, China.

Background: Diffuse leptomeningeal glioneuronal tumor (DLGNT) is a rare mixed neuronal-glial tumor of central nervous system. Chromosome microarray usually identifies co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 as well as fusion of the KIAA1549 and BRAF genes.

Methods: We describe a case of a 3-year-old boy with typical imaging and histopathological features, but without KIAA1549-BRAF fusion and 1p deletion. Read More

View Article and Full-Text PDF
February 2022

Oligosarcomas, IDH-mutant are distinct and aggressive.

Acta Neuropathol 2022 02 30;143(2):263-281. Epub 2021 Dec 30.

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. Read More

View Article and Full-Text PDF
February 2022

Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study.

Radiother Oncol 2022 02 22;167:89-96. Epub 2021 Dec 22.

Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Background And Purpose: Standard of care for recurrent high grade glioma (HGG) is missing. Several treatment options have been investigated including re-irradiation (re-RT). Results are promising but provided by retrospective studies. Read More

View Article and Full-Text PDF
February 2022

[Anterior transperiinsular approach to the head of the caudate nucleus and mediobasal frontal lobe].

Zh Vopr Neirokhir Im N N Burdenko 2021 ;85(6):54-60

Burdenko Neurosurgical Center, Moscow, Russia.

Background: The head of the caudate nucleus and adjacent mediobasal frontal lobe are deeply localized and have complex anatomical and topographic relationships with surrounding functionally significant cerebral structures. These aspects determine difficult surgical treatment of pathology in this zone.

Objective: To propose a new anterior transperiinsular approach for optimizing surgical access to the head of the caudate nucleus and mediobasal frontal lobe. Read More

View Article and Full-Text PDF
December 2021

Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment.

JCI Insight 2022 02 8;7(3). Epub 2022 Feb 8.

Department of Neurology & Interdisciplinary Neuro-Oncology.

The discovery of the oncometabolite 2-hydroxyglutarate in isocitrate dehydrogenase 1-mutated (IDH1-mutated) tumor entities affirmed the role of metabolism in cancer. However, large databases with tissue metabolites that are modulated by IDH1 mutation remain an area of development. Here, we present an unprecedented and valuable resource for tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and tumor treatments in 101 tissue samples from 73 diffuse glioma patients (24 astrocytoma, 17 oligodendroglioma, 32 glioblastoma), investigated by NMR-based metabolomics and supported by RNA-Seq. Read More

View Article and Full-Text PDF
February 2022